Guided Therapeutics, Inc.
GTHP
$0.25
$0.0525.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 650.00K | 767.00K | 767.00K | 178.00K | 118.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 650.00K | 767.00K | 767.00K | 178.00K | 118.00K |
| Cost of Revenue | 157.00K | 195.00K | 195.00K | 66.00K | 41.00K |
| Gross Profit | 493.00K | 572.00K | 572.00K | 112.00K | 77.00K |
| SG&A Expenses | 2.62M | 2.88M | 2.74M | 1.83M | 1.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -219.00K | -217.00K | -- | -- | -- |
| Total Operating Expenses | 2.90M | 3.30M | 3.41M | 2.37M | 2.39M |
| Operating Income | -2.25M | -2.53M | -2.64M | -2.20M | -2.27M |
| Income Before Tax | -3.07M | -3.27M | -3.20M | -2.63M | -2.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.07 | -3.27 | -3.20 | -2.63 | -2.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.07M | -3.27M | -3.20M | -2.63M | -2.54M |
| EBIT | -2.25M | -2.53M | -2.64M | -2.20M | -2.27M |
| EBITDA | -2.24M | -2.52M | -2.63M | -2.19M | -2.26M |
| EPS Basic | -0.04 | -0.05 | -0.04 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 351.66M | 333.96M | 313.42M | 290.39M | 265.74M |
| Average Diluted Shares Outstanding | 351.66M | 333.96M | 313.42M | 290.39M | 265.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |